NASDAQ: KRYS - Krystal Biotech, Inc.

Yield per half year: -8.7%
Dividend yield: 0.00%
Sector: Healthcare

Company Analysis Krystal Biotech, Inc.

Download the report: word Word pdf PDF

1. Summary

Advantages

  • The stock's return over the last year (2.54%) is higher than the sector average (-35.61%).
  • Current debt level 0.6877% is below 100% and has decreased over 5 years from 1.56%.
  • The company's current efficiency (ROE=10.34%) is higher than the sector average (ROE=9.69%)

Disadvantages

  • Price (177.37 $) is higher than fair price (45.1 $)
  • Dividends (0%) are below the sector average (0.5448%).

Similar companies

Alexion

Amgen

ABIOMED

Gilead Sciences

2. Share price and performance

2.1. Share price

2.2. News

No news yet

2.3. Market efficiency

Krystal Biotech, Inc. Healthcare Index
7 days -1.4% -23.6% -2.4%
90 days 8.4% -36.5% -12.5%
1 year 2.5% -35.6% 8.9%

KRYS vs Sector: Krystal Biotech, Inc. has outperformed the "Healthcare" sector by 38.15% over the past year.

KRYS vs Market: Krystal Biotech, Inc. has significantly underperformed the market by -6.39% over the past year.

Stable price: KRYS is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.

Long period: KRYS with weekly volatility of 0.0488% over the past year.

3. Summary of the report

3.1. General

P/E: 53.3
P/S: 16.36

3.2. Revenue

EPS 3
ROE 10.34%
ROA 9.51%
ROIC 0%
Ebitda margin 37.83%

4. Fundamental Analysis

4.1. Stock price and price forecast

The fair price is calculated taking into account the Central Bank refinancing rate and earnings per share (EPS)

Above fair price: The current price (177.37 $) is higher than the fair price (45.1 $).

Price is higher than fair: The current price (177.37 $) is 74.6% higher than the fair price.

4.2. P/E

P/E vs Sector: The company's P/E (53.3) is lower than that of the sector as a whole (57.21).

P/E vs Market: The company's P/E (53.3) is higher than that of the market as a whole (48.7).

4.2.1 P/E Similar companies

4.3. P/BV

P/BV vs Sector: The company's P/BV (5.02) is higher than that of the sector as a whole (4.65).

P/BV vs Market: The company's P/BV (5.02) is higher than that of the market as a whole (3.42).

4.3.1 P/BV Similar companies

4.4. P/S

P/S vs Sector: The company's P/S indicator (16.36) is lower than that of the sector as a whole (33.44).

P/S vs Market: The company's P/S indicator (16.36) is higher than that of the market as a whole (10.24).

4.4.1 P/S Similar companies

4.5. EV/Ebitda

EV/Ebitda vs Sector: The company's EV/Ebitda (40.17) is higher than that of the sector as a whole (-17.68).

EV/Ebitda vs Market: The company's EV/Ebitda (40.17) is higher than that of the market as a whole (25.23).

5. Profitability

5.1. Profitability and revenue

5.2. Earnings per share - EPS

5.3. Past profitability Net Income

Yield Trend: Negative and has fallen by -75.44% over the last 5 years.

Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-75.44%).

Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (156.84%).

5.4. ROE

ROE vs Sector: The company's ROE (10.34%) is higher than that of the sector as a whole (9.69%).

ROE vs Market: The company's ROE (10.34%) is higher than that of the market as a whole (8.97%).

5.5. ROA

ROA vs Sector: The company's ROA (9.51%) is higher than that of the sector as a whole (0.2896%).

ROA vs Market: The company's ROA (9.51%) is higher than that of the market as a whole (6.31%).

5.6. ROIC

ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (7.63%).

ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (10.96%).

6. Finance

6.1. Assets and debt

Debt level: (0.6877%) is quite low in relation to assets.

Debt reduction: over 5 years, the debt has decreased from 1.56% to 0.6877%.

Debt Covering: The debt is covered by 8.14% from net profit.

6.2. Profit growth and share price

7. Dividends

7.1. Dividend yield vs Market

Low yield: The dividend yield of the company 0% is below the average for the sector '0.5448%.

7.2. Stability and increase in payments

Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.

Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.

7.3. Payout percentage

Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.

8. Insider trades

8.1. Insider trading

Insider Buying Exceeds insider sales by 100% over the last 3 months.

8.2. Latest transactions

Transaction date Insider Type Price Volume Quantity
28.02.2025 Krishnan Krish S
President and CEO
Purchase 178.55 5 356 500 30 000
28.02.2025 Krishnan Krish S
President and CEO
Purchase 178.55 8 481 120 47 500
28.02.2025 Krishnan Suma
President, R&D
Purchase 178.55 8 481 120 47 500
11.06.2024 Krishnan Krish S
President and CEO
Sale 175.76 4 394 000 25 000
11.06.2024 Krishnan Suma
President, R&D
Sale 175.77 4 394 250 25 000

Pay for your subscription

More functionality and data for company and portfolio analysis is available by subscription

9. Stocks forum Krystal Biotech, Inc.

9.3. Comments